Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
10.5468/ogs.2019.62.4.285
- Author:
Hyejeong HUE
1
;
Kidong KIM
;
HyoJin KIM
;
Dong Hoon SUH
;
Jae Hong NO
;
Yong Beom KIM
Author Information
1. Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Peritoneal neoplasms;
Neoplasm recurrence, local;
Infusions, parenteral;
Drug therapy;
Ovarian neoplasms
- MeSH:
Carboplatin;
Cisplatin;
Drug Therapy;
Humans;
Infusions, Parenteral;
Neoplasm Recurrence, Local;
Ovarian Neoplasms;
Paclitaxel;
Peritoneal Cavity;
Peritoneal Neoplasms;
Recurrence;
Topotecan
- From:Obstetrics & Gynecology Science
2019;62(4):285-289
- CountryRepublic of Korea
- Language:English
-
Abstract:
The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
